Damora Therapeutics, Inc. (DMRA) Cash Flow Statement
Damora Therapeutics, Inc. (DMRA) generated -$44.5M of operating cash flow over the twelve months to 2026-06-30, spent -$37.8M on capital expenditure and had free cash flow of -$6.7M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DMRADamora Therapeutics, Inc.Follow DMRA — free
—
Price chart with a free account
- Market cap
- 1.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 30 Oct, in 6 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -38.2 | -52.3 | -42.9 | -36.9 | -18.6 | -6.7 | -44.5 | |
| Capital expenditure | — | 0.2 | 0.2 | — | 0.0 | 0.0 | 37.8 | |
| Free cash flow | — | -52.5 | -43.1 | — | -18.6 | -6.7 | -6.7 | |
| Stock-based compensation | 1.0 | 4.5 | 5.6 | 5.4 | 3.2 | 1.0 | — |
USD millions · SEC XBRL
Damora Therapeutics, Inc. — questions
- What is Damora Therapeutics, Inc.'s operating cash flow?
- -$44.5M over the twelve months to 2026-06-30.
- How much does Damora Therapeutics, Inc. spend on capital expenditure?
- -$37.8M over the twelve months to 2026-06-30.
- What is Damora Therapeutics, Inc.'s free cash flow?
- -$6.7M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Damora Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.